AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06234722 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Reduced nicotine regulatory environment
Description: In this regulatory environment, participants' usual combustible cigarette will not be available in the Experimental Tobacco Marketplace and only the participants' assigned investigational cigarette will be the only available combustible cigarette.
Study NCT06234722 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Restriction on characterizing flavors in combustible nicotine products
Description: In this regulatory environment, menthol and other characterizing flavors in combustible nicotine products will not be available in the Experimental Tobacco Marketplace. Only tobacco or no flavored combustible nicotine products will be the only combustible nicotine products available.
Study NCT06234722 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Restriction on characterizing flavors in combustible nicotine products
Description: In this regulatory environment, menthol and other characterizing flavors in combustible nicotine products will not be available in the Experimental Tobacco Marketplace. Only tobacco or no flavored combustible nicotine products will be the only combustible nicotine products available.
Study NCT06234722 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Restriction on characterizing flavors in noncombustible nicotine products
Description: In this regulatory environment, menthol and other characterizing flavors in noncombustible nicotine products will not be available in the Experimental Tobacco Marketplace. Only tobacco or no flavored noncombustible nicotine products will be the only noncombustible nicotine products available.
Study NCT06234722 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Restriction on characterizing flavors in noncombustible nicotine products
Description: In this regulatory environment, menthol and other characterizing flavors in noncombustible nicotine products will not be available in the Experimental Tobacco Marketplace. Only tobacco or no flavored noncombustible nicotine products will be the only noncombustible nicotine products available.
Study NCT04882150 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986196
Description: Specified dose on specified days
Study NCT04882150 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Specified dose on specified days
Study NCT05855577 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Terazosin
Description: Treatment of Terazosine vs placebo and Lisosan-G vs placebo in cross-over double-blind, double-dummy
Study NCT05855577 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Terazosin
Description: Treatment of Terazosine vs placebo and Lisosan-G vs placebo in cross-over double-blind, double-dummy
Study NCT05271786 — intervention group
Intervention type: OTHER
Intervention: Decannulation
Description: retrospective evaluation of decannulation
Study NCT06319625 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Rehabilitation therapy
Description: The study lasted 10d for each patient. During the treatment, All the participants were provided with the rehabilitation therapy, which included routine rehabilitation, cognitive training, swallowing function training and nutrition support.~Particularly, due to dysphagia, the patients enrolled might face difficulty in eating. For patients who were able to finish intake via mouth by compensatory means, the consistency, type, and size of food bolus was arranged. For those who cannot acquire sufficient nutrition through oral intake, the nasogastric tube feeding (NGT) was provided.
Study NCT06319625 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Rehabilitation therapy
Description: The study lasted 10d for each patient. During the treatment, All the participants were provided with the rehabilitation therapy, which included routine rehabilitation, cognitive training, swallowing function training and nutrition support.~Particularly, due to dysphagia, the patients enrolled might face difficulty in eating. For patients who were able to finish intake via mouth by compensatory means, the consistency, type, and size of food bolus was arranged. For those who cannot acquire sufficient nutrition through oral intake, the nasogastric tube feeding (NGT) was provided.
Study NCT06319625 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stellate ganglion block
Description: Based on the invention above, the patients in the observation group were provided with Stellate ganglion block , using 1.5ml of 2% Lidocaine hydrochloride (1ml: 0.5mg) and 500ug of Vitamin B12 (1ml: 0.5g). The percutaneous approach via the paratracheal route was used for Stellate ganglion block . The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck.
Study NCT06319625 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine hydrochloride
Description: Based on the invention above, the patients in the observation group were provided with Stellate ganglion block , using 1.5ml of 2% Lidocaine hydrochloride (1ml: 0.5mg) and 500ug of Vitamin B12 (1ml: 0.5g). The percutaneous approach via the paratracheal route was used for Stellate ganglion block . The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck.
Study NCT06319625 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo injection
Description: 1 milliliter of normal saline will be used for injection. The percutaneous approach via the paratracheal route was used for Stellate ganglion block . The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck.
Study NCT05499572 — intervention group
Intervention type: DEVICE
Intervention: Inhalation maneuver with placebo Inbrija and placebo Cyclops
Description: Patients perform the inhalation maneuvers with placebo inhalers (Inbrija and Cyclops) during a Parkinson's off episode.
Study NCT04767477 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Face-to-face rehabilitation
Description: Aerobic training will be performed with 60% to 80% of the maximum VO2 obtained through the CPET. The exercise will be performed on the treadmill, with a total time of 40 minutes, with 5 minutes of warm-up, 30 minutes of conditioning, 5 minutes of cooling down. Resistance training will be performed for upper and lower limbs and the load used in the exercises will be 60% of the maximum repetition test (1RM), with load progression every six sessions. The exercises are performed in three series of 12 repetitions.
Study NCT04767477 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Telerehabilitation
Description: The telerehabilitation protocol will consist of stretching the muscles of the upper and lower limbs and accessory muscles of breathing. The conditioning phase will consist of stationary walking, side running, jumping jump and stationary running, 3 times of 40 seconds with a 30-second passive rest interval between them. Resistance training will be applied to the muscles of the upper limbs and lower limbs, with specific exercises for each musculature, using elastic bands as resistance.
Study NCT04306107 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Prone position during non-invasive respiratory support
Description: HFNC and NIV application with patient on prone position
Study NCT04306107 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Prone position during non-invasive respiratory support
Description: HFNC and NIV application with patient on prone position
Study NCT06322420 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioural Activation (BA)
Description: Behavioural activation treatment delivered in this single arm study. Individual treatment given to all participants in 12 sessions over 11 weeks. All treatment components have been introduced by session 8 that defines minimum amount of treatment in the trial (i.e. 8 session completed).~Behavioral Activation is a psychological treatment for depression focused on gradually re-engaging people with sources of reinforcement and reward in their environment by re-establish healthy patterns of activity, and replace avoidance behaviours with more adaptive behaviours.
Study NCT06176326 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ethics Education Program in Nursing
Description: In the 7-session training program, each session, lasting 2 hours, presented to students the topic headings determined through the needs analysis of the program development study. This education program consists of sessions on the Introduction to Ethics-Bioethics, Principles of Beneficence and Non-maleficence, Autonomy and Responsibility, Informed Consent and Those Lacking Capacity for Consent, Respect for Human Vulnerability and Individual Integrity, Respect for Private Life and Ensuring Confidentiality, Discrimination, Stigmatization, and Cultural Diversity.
Study NCT05493514 — intervention group
Intervention type: DEVICE
Intervention: Robotic Assisted Gait Training with G-EO system
Description: Robotic-assisted gait training is a rehabilitation treatment that applies robotic technologies to improve mobility of patients with stroke or other neurological disorders. In this study, participants will use the G-EO system robotic device according to the daily clinical practice of the Don Gnocchi Foundation.
Study NCT05381350 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: COVID-19 Vaccine (Vero cell), Inactivated (Omicron variant)
Description: The COVID-19 Vaccine (Vero cell), Inactivated (Omicron variant)was manufactured by Sinovac Research\& Development Co., Ltd.1200SOU inactivated SARS-CoV-2 Omicron strain in 0.5ml of aluminium hydroxide solution per injection.
Study NCT05381350 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: COVID-19 Vaccine (Vero cell), Inactivated (CZ strain)
Description: The COVID-19 vaccine,inactivated was manufactured by Sinovac Research\& Development Co., Ltd.600SU inactivated SARS-CoV-2 CZ strain virus in 0.5 mL of aluminium hydroxide solution per injection.
Study NCT04948931 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lavender aromatherapy
Description: The application will be once a day, every day for four weeks. Each session will take five minutes.
Study NCT04948931 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rosemary aromatherapy
Description: The application will be once a day, every day for four weeks. Each session will take five minutes.
Study NCT04948931 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: The application will be once a day, every day for four weeks. Each session will take five minutes.
Study NCT05527548 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alendronate (ALN)
Description: The oral ALN is the first-line therapy for osteoporosis, and it has been proven that once-weekly ALN 70 mg is an effective and well-tolerated dose for the treatment of postmenopausal osteoporosis. In this study, after receiving the approval of CREC and the Department of Health, we will purchase ALN from drug store. Previous clinical studies have shown that oral administration of ALN at 70mg/week for 1 year and at 5mg/day for 2 years reduced bone loss in postmenopausal women and patients who underwent total hip arthroplasty, respectively. Therefore, in the proposed study, ALN at the dose of 70mg/week will be given to patients post-ACLR for a duration of 8 weeks.
Study NCT05001022 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALG-020572
Description: Single or multiple doses of ALG-020572
Study NCT05001022 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single or multiple doses of Placebo
Study NCT05000658 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone phosphate
Description: HSC injection of 4mL
Study NCT05000658 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dexamethasone phosphate
Description: HSC injection of 4mL
Study NCT05133817 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Simultaneous with spinal anesthesia, 500 mL 6% Hydroxyethyl starch (130/0.4) coload was given and a maintenance dose of normal saline by IV infusion.
Study NCT05133817 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Norepinephrine (0.025 μg/kg/min)
Description: Simultaneous with spinal anesthesia, 500 mL 6% Hydroxyethyl starch (130/0.4) coload was given and a different maintenance dose of norepinephrine by IV infusion.
Study NCT05133817 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Norepinephrine (0.05 μg/kg/min)
Description: Simultaneous with spinal anesthesia, 500 mL 6% Hydroxyethyl starch (130/0.4) coload was given and a different maintenance dose of norepinephrine by IV infusion.
Study NCT05133817 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Norepinephrine (0.075 μg/kg/min)
Description: Simultaneous with spinal anesthesia, 500 mL 6% Hydroxyethyl starch (130/0.4) coload was given and a different maintenance dose of norepinephrine by IV infusion.
Study NCT05133817 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Norepinephrine (0.1 μg/kg/min)
Description: Simultaneous with spinal anesthesia, 500 mL 6% Hydroxyethyl starch (130/0.4) coload was given and a different maintenance dose of norepinephrine by IV infusion.
Study NCT05595590 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: Administered as an intravenous (IV) infusion 200mg every 3 weeks (Q3W)
Study NCT05595590 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Pulse radiation
Description: 66-70Gy/33-35Fx, 2Gy/Fx.
Study NCT05207475 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Remote ischemic conditioning
Description: RIC is a non-invasive therapy that performed by an electric auto-control device with cuff placed on arm. RIC procedures consist of five cycles of 5-min inflation (200 mmHg) and 5-min deflation of cuff on one arm. The procedure will be performed twice daily for consecutive 1 years after enrollment.
Study NCT04736823 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK112
Description: IV infusion
Study NCT04736823 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: IV infusion
Study NCT04736823 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: IV infusion
Study NCT04736823 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: IV infusion
Study NCT04736823 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: IV infusion
Study NCT06644989 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Spencer Technique
Description: Spencer technique on the hip
Study NCT06644989 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham (No Treatment)
Description: Spencer technique position but no pressure
Study NCT05345470 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: 140 calories per 30 gram test meal
Description: Food
Study NCT05345470 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 140 calories per 30 gram test meal
Description: Food
Study NCT04829045 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SEIRIN PYONEX Acupuncture Needles
Description: 10 press needles (PYONEX ø0.20×1.5mm made by Seirin Corporation) will be placed on abdomen area; 10 sessions over 6 weeks.
Study NCT04829045 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: PYONEX Placebo
Description: Subjects are given placebo on abdomen area; 10 sessions over 6 weeks.
Study NCT04492553 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AndroGel
Description: Treatment indication: hypogonadism after cancer treatment. Dosage: 1-2 sachets a day. Follows standard treatment.
Study NCT02747914 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial magnetic stimulation
Description: TMS 1Hz under the motor zone of cortex.
Study NCT02747914 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional exercise
Description: Exercise will be administrated in a conventional way.
Study NCT06129630 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional occupational therapy sessions.
Description: Occupational therapy sessions are based on cognitive stimulation, manipulative dexterity training and psychomotor skills.
Study NCT06129630 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Conventional occupational therapy sessions + Nintendo Switch
Description: Occupational therapy sessions are based on cognitive stimulation, manipulative skill training and psychomotor skills. In addition, 2 sessions per week are conducted with two Nintendo Switch games.
Study NCT05824325 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-A1811
Description: HER2 ADC
Study NCT05824325 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TROP2 ADC
Description: TROP2 ADC
Study NCT04828824 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ethinyl Estradiol / Norgestimate Oral Tablet
Description: Those who desire COCs as an intervention are prescribed (over the phone) or given (in person) 3 packs of COCs. They are told to take one pill per day until the first pack is complete and save the remaining 2 packs for possible future use.
Study NCT05669742 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Empagliflozin
Description: sodium-glucose transport protein two inhibitor
Study NCT05669742 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: olanzapine
Description: antipsychotics
Study NCT04739839 — intervention group
Intervention type: OTHER
Intervention: survey questionnaire
Description: Questionnaire focusing on low back pain in relation to life style, physical activity level, illness perception and quality of life.
Study NCT04976452 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multi-component teaching content
Description: The students assigned to Group 1 will undergo interactive module training by the American Medical Association which outlines how to properly measure blood pressure manually following the American Heart Association guidelines. Following completion of the module, students will be presented with a powerpoint lecture by the Primary Investigator on Blood Pressure. Students will then undergo a competency examination that assesses their ability to measure blood pressure following the guidelines of the American Heart Association.
Study NCT05422092 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canagliflozin
Description: 40 patients with T2DM combined with NAFLD, who have poor glycemic control response to metformin monotherapy, will be randomly assigned to receive canagliflozin on top of metformin as experimental group.
Study NCT05422092 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Pioglitazone
Description: 40 patients with T2DM combined with NAFLD, who have poor glycemic control response to metformin monotherapy, will be randomly assigned to receive pioglitazone 45mg on top of metformin as placebo comparator group.
Study NCT05674448 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HH-003 20mg/kg
Description: HH-003 20mg/kg Q2W intravenously for 24 weeks
Study NCT05674448 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HH-003 3mg/kg
Description: HH-003 3mg/kg Q2W intravenously for 24 weeks
Study NCT05365113 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: alveolar recruitment maneuver
Description: When patient is under general anesthesia, an arterial catheter is placed for cardiac output and stroke volume (SV) monitoring. To avoid pre-load dependency bias, the blood volume will be optimized. A 250mL fluid-challenge of a balanced crystalloid solution is administered under cover of the SV monitoring. If SV variation is greater than 10%, a new fluid-challenge is performed to obtain a reference SV, corresponding to the patient's optimal blood volume.The patient is then pre-load independent.~Then, patients will be randomized into two groups: a first group will receive a CPAP ARM: 40 cmH2O for 50 seconds, followed by a 10-minute break corresponding to a period of return to basal state; then an extended sigh ARM (e-sigh) also lasting 50seconds (driving pressure: 10cmH2O and successive PEEP levels at 10,15,20,25 and 30cmH2O, a respiratory rate set at 30/min in controlled pressure - 5cycles at each PEEP level); a second group will receive the same two ARM modalities in reverse order.
Study NCT06407622 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Foot Reflexology
Description: In previous studies, no study was found investigating the effect of foot reflexology on sleep quality and bowel functions in patients undergoing surgical intervention. This study is thought to be the first to evaluate the effect of foot reflexology on sleep quality and bowel functions in surgical patients. In this respect, it is a study that will contribute to the literature.
Study NCT06161103 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 3D Printed Prefabricated Composite Resin Crown Group
Description: 3D Crown application: After preparing the molars, the crown was cemented by passive seating with modified glass ionomer cement (GC FujiCEM Evolve, GC America, Alsip, USA).